8-K: Aardvark Expands PWS Trial Eligibility to Ages 10+

Aardvark Therapeutics announced FDA alignment on a protocol amendment to its Phase 3 HERO trial for Prader-Willi Syndrome, lowering the minimum age of eligibility from 13 to 10 years old.

Summary

• Aardvark Therapeutics, Inc. (Nasdaq: AARD) announced alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment for its Phase 3 HERO trial of ARD-101.
• The trial is evaluating ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS).
• The protocol amendment changes the minimum age of eligibility to participate in the trial from 13 years old to 10 years old.
• This expansion aims to reach a larger segment of the PWS patient population, potentially serving more patients in need.
• Management believes this decision is supported by the PWS community and historical data indicating that younger patients are more likely to benefit from early intervention.
• Topline data readout for the Phase 3 HERO trial is anticipated in the third quarter of 2026.
• ARD-101 is a gut-restricted small molecule agonist of select taste receptors (TAS2Rs), stimulating enteroendocrine cells to release gut-peptide hormones like GLP-1 and Cholecystokinin (CCK), which mediate hunger.
• ARD-101 has been granted both Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for PWS.

Sentiment

Score: 8

Explanation: The FDA alignment and expansion of the trial population are significant positive developments for the Phase 3 HERO trial, potentially improving its success rate and market reach. While standard clinical trial risks remain, this specific update is favorable.

Positives

• FDA alignment on the protocol amendment indicates regulatory support and reduces uncertainty for the Phase 3 HERO trial.
• Expanding trial eligibility to include children 10 years of age and older broadens the potential patient population for ARD-101, which could accelerate enrollment and increase the trial's statistical power.
• Management's belief, supported by historical data, that younger patients benefit more from early intervention suggests a potentially more effective treatment outcome for the expanded cohort.
• ARD-101 holds Orphan Drug Designation and Rare Pediatric Disease Designation for PWS, which can provide development incentives and market exclusivity upon approval.

Risks

• Uncertainties related to potential delays in the commencement, enrollment, and completion of clinical trials.
• Risk that capital resources may be used sooner than expected and be insufficient to achieve anticipated milestones.
• Risks related to dependence on third parties for manufacturing, shipping, and production of drug product for clinical and preclinical trials.
• Risk of unfavorable clinical trial results.
• Risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.
• Other risks and uncertainties, including factors described in Aardvark's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 13, 2025.

Future Outlook

Aardvark expects topline data readout for the Phase 3 HERO trial in the third quarter of 2026. The company believes the expanded eligibility will allow them to serve more patients and that younger patients are more likely to benefit from early intervention.

Management Comments

• "Expansion of the Phase 3 HERO trial to include children 10 years of age and older will allow us to reach a larger segment of the PWS patient population to potentially serve more patients in need."
• "This decision to expand eligibility is driven by support from the PWS community, alongside historical data showing that younger patients are more likely to benefit from early intervention."
• "We look forward to our topline data readout for this potentially pivotal trial in the third quarter of 2026."

Industry Context

The biopharmaceutical industry frequently adjusts clinical trial protocols based on new data or regulatory feedback to optimize patient recruitment and trial success. The focus on rare diseases like PWS, with specific designations (Orphan Drug, Rare Pediatric Disease), highlights a common strategy for companies to address unmet medical needs and potentially gain market exclusivity. The mention of ARD-101's mechanism (TAS2Rs, GLP-1, CCK) and its potential complementary use with GLP-1 therapies positions Aardvark within the broader metabolic disease and obesity treatment landscape, where GLP-1 agonists represent a significant and growing market.

Stakeholder Impact

• Shareholders: Positive impact due to increased likelihood of trial success and broader market potential for ARD-101, potentially leading to increased share value.
• Patients (Prader-Willi Syndrome community): Highly positive impact as more younger patients (ages 10-12) will have access to a potentially life-changing treatment through the clinical trial.
• Regulatory Authorities (FDA): Continued collaboration and alignment on trial protocols.
• Employees: Positive impact from progress in the lead clinical program.

Next Steps

• Continue the Phase 3 HERO trial with the amended protocol.
• Anticipate topline data readout for the Phase 3 HERO trial in the third quarter of 2026.
• Further development of ARD-201 (a fixed-dose combination of ARD-101 with a DPP-4 inhibitor) for obesity and obesity-related conditions.

Key Dates

Recommendation

The FDA's alignment on expanding the Phase 3 HERO trial to include younger patients (10-12 years old) for ARD-101 in Prader-Willi Syndrome is a significant positive catalyst. This move broadens the potential patient population, potentially accelerates trial enrollment, and aligns with management's view that earlier intervention is beneficial. The Orphan Drug and Rare Pediatric Disease designations further de-risk the development pathway and offer market exclusivity potential. While clinical trials inherently carry risks, this specific update improves the probability of success and future market opportunity for ARD-101, making Aardvark Therapeutics a more attractive investment.

Keywords

Aardvark Therapeutics, ARD-101, Prader-Willi Syndrome, PWS, hyperphagia, Phase 3 HERO trial, FDA, clinical trial, biopharmaceutical, Orphan Drug, Rare Pediatric Disease, metabolic diseases, GLP-1, CCK